Drug intelligence / Profile preview

Jinbei Breastcare

Development stage: Unknown
Lead developer: Huahong Pharmaceutical
Administration: Oral

Overview

Jinbei Breastcare (also known as Jinbei Rukang) is a traditional Chinese medicine (TCM) tablet formulation developed for the treatment of mammary gland hyperplasia, specifically targeting the phlegm and blood stasis syndrome pattern. The herbal formula was originated by the Beijing Hospital of Traditional Chinese Medicine, with further development and clinical trial sponsorship by Beijing Yingkerui Drug Research Institute and Guangxi Huahong Pharmaceutical. It has been evaluated in Phase II clinical trials in China to assess its efficacy, safety, and optimal dosage in patients with hyperplasia of mammary glands.

Other names: Jinbei Breastcare tabletsJinbei RukangJinbei Rukang tablets金贝乳康片

Beyond the preview

Go deeper on Jinbei Breastcare.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinbei Breastcare.

Explore the full profile